^
    The oncoReveal™ Dx Colon Cancer Assay is a companion diagnostic test that identifies patients with metastatic colorectal cancer who have KRAS wild-type tumor status and may benefit from treatment with approved therapies, Erbitux® (cetuximab) or Vectibix® (panitumumab). The assay utilizes Pillar’s highly accurate and sensitive SLIMamp® NGS testing technology to generate data that optimizes selection of precision therapies for cancer patients.
    Cancer:
    Colorectal Cancer
    Gene:
    KRAS (KRAS proto-oncogene GTPase)
    Drug:
    Erbitux (cetuximab), Vectibix (panitumumab)
    Method:
    Next-Generation Sequencing (NGS)